FilingSEC EDGAR8-K
BioAge Labs Initiates First Patient Dosing in Phase 2 Trial for Diabetic Macular Edema Treatment
· SEC accepted
StagePhase 2
Filing content
The company has dosed the first participant in its Phase 2 QUELL-DME trial evaluating BGE-102 for diabetic macular edema.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…